

# Albus

Albumin Awards Program



# Albus Albumin Awards Program

### ABOUT THE ALBUS AWARDS

Albus is a program whose aim is to foster a scientific network, to increase the knowledge in the use of albumin as a therapeutic product and to encourage discovery of beneficial albumin applications.

By supporting this program, Grifols demonstrates its commitment to innovation in this field. We consider the program to be a tangible contribution to the improvement of standards, and a benefit to patient care.

## ABOUT THE ALBUS PROGRAM

Albus is an annual international awards program focused on innovative ideas involving albumin and its role as a therapeutic product. Proposals may include, but are not limited to, projects on: efficacy, mechanism of action, safety and tolerability, quality of life and pharmacoeconomics.

#### The program offers 2 awards of $\in$ 50,000 each to applicants whose proposals best match the program objectives, as assessed by an independent review committee.

Albus aims to:

- Develop novel concepts in albumin research.
- Encourage discovery of beneficial albumin applications.
- Further investigate mechanisms of action or clinical effects in different indications.

### WHO CAN APPLY

Scientists or clinicians with an innovative idea relevant to albumin research. Applications are encouraged from both individuals and teams who may be undertaking research at hospitals, universities, or independent institutions.

Applicants must meet the following eligibility requirements to be considered for an Albus award:

- Applicants must present a focused project with goals that can be achieved within 12 months.
- Applicants must be employed or supported by an institution.

#### **REVIEW BOARD**

#### **Vicente Arroyo (Chair)**

Chairman of the European Association for the Study of the Liver-Chronic Liver Failure Consortium. Director of the Grifols Chair.

Barcelona, Spain.

#### **Antonio Artigas**

Emerit Director of the Critical Care Center and Full Professor of Applied Physiology. Department of Medicine, UAB. Corporació Sanitaria Parc Taulí, Sabadell (Barcelona), Spain.

#### Luciano Gattinoni

Professor in Anesthesiology, Emergency and Intensive Care Medicine. Georg-August University of Göttingen. Göttingen, Germany.

#### **Marco Ranucci**

Head of the Cardiothoracic Anesthesia Department. Director of Clinical Research in the Dept. of Anesthesia and Intensive Care. IRCCS Policlinico San Donato. Milan, Italy.

#### Rajiv Jalan

Professor of Hepatology. University College London. Institute for Liver and Digestive Health Royal Free Hospital. London, UK.

#### **Greg Martin**

Associate Professor of Medicine and Associate Division Director for Critical Care. Emory University. Atlanta, GA, USA.

#### **Bruce Spiess**

Professor and Associate Chair (Research). Department of Anesthesiology. University of Florida College of Medicine. Gainesville, FL, USA.

#### Francisco Mota, Pharm D, MSc

(non-voting Executive Secretary) Associate Director Medical Affairs Intensive Care - EU/ROW Grifols S.A.

## TIMELINES FOR THE ALBUS PROGRAM\*

Letter of intent submission: Every year from November 1<sup>st</sup> to April 30<sup>th</sup>

Awardee announcement: July

Additional information on the grant program, detailed timelines, the constitution of the review board and the application process can be found on our website: www.grifols.com or www.grifolsscientificawards.com

### EVALUATIONS AND SELECTION OF RESEARCH PROPOSALS

Applications are evaluated based on merit, innovation, impact, and research environment/qualification of the applicant. A Review Board of external experts and one Grifols expert in albumin (secretary) assess and rank the grant applications.



\* This schedule is subject to change. Changes will be reflected in our website. http://www.albus-awards.com/en/ web/albus/home


## GRIFOLS SCIENTIFIC AWARDS













Award for Scientific Progress in Immunodeficiency Research

## GRIFOLS